Long-term propranolol therapy in muscular subaortic stenosis.
TLDR
It is indicated that propranolol is most effective in patients with muscular subaortic stenosis who have latent obstruction, and it is of limited value in patientsWith resting obstruction because the benefit of propr ethanol therapy in the majority of these patients is eventually overtaken by progression in the disease.Abstract:
Twenty-one patients with muscular subaortic stenosis were treated with oral propranolol for periods of 6 to 34 months for a total of 42.5 patient years. The average follow-up was 2 years. Four patients with latent obstruction became asymptomatic on propranolol therapy. Of the 17 patients with resting obstruction, 7 improved, 2 were unchanged, 5 deteriorated, and 2 died during the period of treatment. The 7 patients with resting obstruction who are still improved on propranolol have had relatively short periods of treatment (average 15 months), and none experienced the degree of improvement that occurred in the patients with latent obstruction. This study indicates that propranolol is most effective in patients with muscular subaortic stenosis who have latent obstruction. It is of limited value in patients with resting obstruction because the benefit of propranolol therapy in the majority of these patients is eventually overtaken by progression in the disease.read more
Citations
More filters
Journal ArticleDOI
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)
Perry M. Elliott,Aris Anastasakis,Michael A. Borger,Martin Borggrefe,Franco Cecchi,Philippe Charron,Albert Hagège,Antoine Lafont,Giuseppe Limongelli,Heiko Mahrholdt,William J. McKenna,Jens Mogensen,Petros Nihoyannopoulos,Stefano Nistri,Petronella G. Pieper,Burkert Pieske,Claudio Rapezzi,Frans H. Rutten,Christoph Tillmanns,Hugh Watkins +19 more
TL;DR: The objective of this study was to establish a baseline level of confidence that the once-in-a-lifetime implantation trial—Reduce Inappropriate Therapy protocol can be trusted to provide safe and effective treatment for cardiac arrhythmia and stroke-like episodes.
Journal ArticleDOI
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Bernard J. Gersh,Barry J. Maron,Robert O. Bonow,Joseph A. Dearani,Joseph A. Dearani,Michael A. Fifer,Mark S. Link,Srihari S. Naidu,Rick A. Nishimura,Steve R. Ommen,Harry Rakowski,Christine E. Seidman,Jeffrey A. Towbin,James E. Udelson,Clyde W. Yancy +14 more
TL;DR: This information is current as of May 14, 2012 and located on the World Wide Web at: http://content.onlinejacc.org/cgi/content/full/58/25/2703.
Journal ArticleDOI
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
Bernard J. Gersh,Barry J. Maron,Robert O. Bonow,Joseph A. Dearani,Michael A. Fifer,Mark S. Link,Srihari S. Naidu,Rick A. Nishimura,Steve R. Ommen,Harry Rakowski,Christine E. Seidman,Jeffrey A. Towbin,James E. Udelson,Clyde W. Yancy +13 more
TL;DR: Alice K. Jacobs, PhD, CCNS, CCRN, FAHA, Chair, 2009–2011; Sidney C. Smith, Jr, MD, FACC,FAHA, Immediate Past Chair, 2006–2008; Jeffrey L. Anderson,MD, F ACC, FA HA, Chair-Elect.
Journal ArticleDOI
Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review
E.Douglas Wigle,Zion Sasson,Mark A. Henderson,Terrence D. Ruddy,John C. Fulop,Harry Rakowski,William G. Williams +6 more
TL;DR: The extent of hypertrophy is believed to be the principal determinant of the impaired left ventricular relaxation and increased chambers stiffness that characterize diastole in hypertrophic cardiomyopathy.
Journal ArticleDOI
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy
Bernard J. Gersh,Barry J. Maron,Robert O. Bonow,Joseph A. Dearani,Michael A. Fifer,Mark S. Link,Srihari S. Naidu,Rick A. Nishimura,Steve R. Ommen,Harry Rakowski,Christine E. Seidman,Jeffrey A. Towbin,James E. Udelson,Clyde W. Yancy,Alice K. Jacobs,Sidney C. Smith,Jeffrey L. Anderson,Nancy M. Albert,Christopher E. Buller,Mark A. Creager,Steven M. Ettinger,Robert A. Guyton,Jonathan L. Halperin,Judith S. Hochman,Harlan M. Krumholz,Frederick G. Kushner,E. Magnus Ohman,Richard L. Page,William G. Stevenson,Lynn G. Tarkington +29 more
TL;DR: This paper aims to provide a history of FACC/FAHA accreditation practices in the United States from 1989 to 2002, a period chosen in order to explore its role in the development of post-secondary education.
References
More filters
Journal ArticleDOI
Idiopathic Hypertrophic Subaortic Stenosis: I. A Description of the Disease Based Upon an Analysis of 64 Patients
TL;DR: The finding of a murmur before the age of 1 year in 9 of the 64 patients, and the reports of IHSS in a stillborn baby and in several infants, as well as the association of IhSS with congenital cardiac malformations, all support the concept that the disease may, at least in some instances, be congenital.
Journal ArticleDOI
Idiopathic Hypertrophic Subaortic Stenosis Clinical Analysis of 126 Patients with Emphasis on the Natural History
Stuart J. Frank,Eugene Braunwald +1 more
TL;DR: The clinical courses of 126 patients with hemodynamically documented IHSS, examined repeatedly for up to 12 years, were analyzed, and the patients who were asymptomatic initially tended to remain so, while those who were more disabled generally deteriorated, died, or improved spontaneously.
Journal ArticleDOI
Ultrasound Localization of Left Ventricular Outflow Obstruction in Hypertrophic Obstructive Cardiomyopathy
TL;DR: This specific abnormality of mitral leaflet movement represents the localization of dynamic outflow obstruction in hypertrophic obstructive cardiomyopathy.